Recent Updates
Recently added Catalysts
ZLAB

Update on Amgen’s bemarituzumab Phase 1b/3 FORTITUDE-102 Study

Tuesday, November 4, 2025 1 min read
Key Takeaway: Update on Amgen’s bemarituzumab Phase 1b/3 FORTITUDE-102 Study

Full Press Release Details

Update on Amgen’s bemarituzumab Phase 1b/3 FORTITUDE-102 Study.
Tags: ZLAB Viatris Investor Conferences Healthcare investor conferences healthcare conferences UBS Global Healthcare
Last updated: Nov 4, 2025